HanchorBio Participated in Sino-American Pharmaceutical Professionals Association (SAPA) Annual Conference 漢康生技參加美中製藥專業協會（SAPA）年會

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.2022年8月5日，漢康生技——一家致力於成為開發下一代免疫療法先驅者的生物技術公司，宣佈成功完成了約計2000萬美金的A輪融資交割。本次A輪融資的資金將使漢康生技能夠進一步擴大和加速其不斷增長的專有“基於Fc設計的生物製藥（FBDB™）”管線研發進程，並將進一步支援擬申報新藥在臨床前研究階段（IND-enabling）的GLP毒理研究、新藥申報以及後續第一部分的臨床I期試驗。